Halaven filed in EU for earlier-line breast cancer
This article was originally published in Scrip
Executive Summary
Eisai has filed a marketing authorization application in the EU for its novel oncology drug Halaven (eribulin mesylate) in the earlier line treatment of metastatic breast cancer, in a move that could open up a broader therapeutic and commercial market for the microtubule dynamics inhibitor.